论文部分内容阅读
欧洲和美国的研究人员报告,使用罗苏伐他汀(rosuvastatin)降低LDL胆固醇比阿伐他汀(atorvastatin)有更好的成本-效益比,文章发表于Int J Cardiol杂志。阿斯利康英国有限公司的Dr．Mark Hirsch及其同事指出,昂贵的血脂干预费用使确定有最佳成本-效益比的药物变得特别重要。研究者分析了罗
Researchers in Europe and the United States report that using rosuvastatin to lower LDL cholesterol has a better cost-benefit ratio than atorvastatin, which is published in Int J Cardiol. AstraZeneca UK Ltd’s Dr. Mark Hirsch and colleagues point out that the cost of expensive lipid interventions makes drugs that determine the best cost-effectiveness ratio of particular importance. The researchers analyzed Luo